Search results for "korea"

This work was supported by the Seed Program for Korean Studies under the auspices of the Republic of Korea Ministry of Education and the Korean Studies Promotion Service of the Academy of Korean Studies.

Korejiešu vietējie dieviService (business)Korejiešu šamanismsbusiness.industryKorean studiesmedia_common.quotation_subject:HUMANITIES and RELIGION [Research Subject Categories]Korejiešu reliģijaKorean Local GodsPublic relationsKorean MythsKorejas modernā literatūraThe RepublicModern Literature in KoreaPromotion (rank)Work (electrical)Korean ReligionsPolitical scienceSpiritualityChristian ministryKorean Shamanismbusinessmedia_common

researchProduct

Time-series analyses of species richness and relative abundances at the local scale: some methodological advices to secure the relevance of interpret…

2020

Lepidoptera[SDE.BE] Environmental Sciences/Biodiversity and EcologyButterflyKoreaPapillonsGariwang-sanLépidoptèresnumerical extrapolationextrapolation numériqueCoréebiodiversitybiodiversité

researchProduct

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab pl…

2019

10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC. This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined.…

Male0301 basic medicineCancer ResearchEsophageal NeoplasmsReceptor ErbB-2SURGERYmedicine.medical_treatmentGastroenterologyStudy ProtocolNEOADJUVANT CHEMOTHERAPYAntineoplastic Agents Immunological0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesOXALIPLATINNetherlandsAged 80 and overDOCETAXELMiddle AgedOPEN-LABELlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChemotherapy regimenNeoadjuvant TherapyProgression-Free SurvivalTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleGastro-esophageal junction cancerEsophagogastric JunctionFluorouracilPertuzumabmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsCAPECITABINEAdenocarcinomaAntibodies Monoclonal Humanizedlcsh:RC254-282CapecitabineYoung Adult03 medical and health sciencesBreast cancerStomach NeoplasmsInternal medicineHER2Republic of KoreaREGRESSIONGeneticsmedicineHumansBREAST-CANCERPerioperative PeriodAgedCisplatinChemotherapyPerioperative chemotherapyPertuzumabbusiness.industryTrastuzumabmedicine.diseaseOxaliplatin030104 developmental biologyCisplatinbusinessGastric cancerFollow-Up Studies

researchProduct